Review
Oncology
Isacco Ferrarini, Andrea Bernardelli, Ester Lovato, Alberto Schena, Mauro Krampera, Carlo Visco
Summary: Classical Hodgkin lymphoma (cHL) is a unique neoplastic ecosystem with a diverse immune infiltrate, including tumor-infiltrating macrophages that play a key role in supporting malignant Hodgkin Reed-Sternberg cells. Traditional methods have yielded controversial results about the composition and function of macrophages in cHL, but more recent studies utilizing single-cell technologies have revealed the heterogeneity and spatial arrangement of macrophagic infiltrate. High-throughput analysis of peripheral blood mononuclear cells has also identified a novel subpopulation that predicts better response to PD-1 blockade. This review provides an up-to-date portrait of tumor-infiltrating macrophages and circulating monocytes in cHL, with potential translational applications.
FRONTIERS IN ONCOLOGY
(2023)
Review
Medicine, General & Internal
Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg
Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.
Article
Hematology
Dennis A. Eichenauer, Horst Muller, Leonard Elger, Helen Goergen, Michael Fuchs, Stefanie Kreissl, Boris Boll, Volker Diehl, Bastian von Tresckow, Peter Borchmann, Andreas Engert
Summary: NHL after cHL is a rare event that primarily affects older individuals, with a five-year event-free survival and overall survival estimates of 36.9% and 44.2% respectively.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Medicine, General & Internal
Julian Benckendorff, Johanna Kuchar, Frank Leithauser, Malena Zahn, Peter Moller
Summary: The study found that BATF3, an AP-1 transcription factor, is highly expressed in Hodgkin lymphoma and anaplastic large cell lymphoma. By analyzing BATF3 scores, it was observed that BATF3 expression is low to moderate in other lymphoma entities. Therefore, BATF3 can be considered as a useful diagnostic marker for classical Hodgkin lymphoma.
Review
Oncology
Naike Casagrande, Cinzia Borghese, Donatella Aldinucci
Summary: In classical Hodgkin Lymphoma (cHL), the tumor microenvironment (TME) has a significant impact on tumor progression and treatment response. This review focuses on the emerging approaches for analyzing TME composition and evaluating the disease state, as well as in vitro techniques to study the immunosuppressive and protective TME. The development of new 3-dimensional models, such as heterospheroids (HS), has also provided valuable insights into TME interactions. The results of these studies have important implications for the clinical application of new anticancer drugs and the understanding of drug resistance mechanisms in cHL.
Article
Oncology
Alex Reza Gholiha, Peter Hollander, Liza Loef, Anders Larsson, Jamileh Hashemi, Johan Mattsson Ulfstedt, Daniel Molin, Rose-Marie Amini, Eva Freyhult, Masood Kamali-Moghaddam, Gunilla Enblad
Summary: The proximity extension assay (PEA) method was used to identify immune-related proteins that distinguish diagnostic classic Hodgkin Lymphoma (cHL) tissues from control tissues. The study found several proteins that are elevated in both cHL tissues and cHL plasma compared to control samples, and these proteins are also significantly correlated to PD-L1 expression in cHL tissue.
Article
Hematology
Alex Reza Gholiha, Peter Hollander, Ingrid Glimelius, Gustaf Hedstrom, Daniel Molin, Henrik Hjalgrim, Karin E. Smedby, Jamileh Hashemi, Rose-Marie Amini, Gunilla Enblad
Summary: IL-6 expression in the tumor microenvironment is associated with adverse survival outcomes in patients with classical Hodgkin lymphoma, while not correlated with other immune markers or serum IL-6 levels.
Review
Oncology
Arina Martynchyk, Rakin Chowdhury, Eliza A. Hawkes, Colm Keane
Summary: Approximately 15% of classical Hodgkin lymphoma (cHL) patients experience relapsed or refractory (RR) disease despite standard treatment. Targeted agents such as anti-PD-1 agents and brentuximab vedotin have improved therapy beyond chemotherapy and radiotherapy. The tumour microenvironment (TME) of cHL, characterized by immune-rich composition, plays a crucial role in disease progression and treatment response. Advances in high-throughput technologies and single-cell sequencing have allowed deeper analysis of the TME and understanding of the interactions between immune cells and malignant Hodgkin Reed-Sternberg cells. This review provides insights into the evolving understanding of the prognostic role of immune cells within the TME and presents emerging prognostic data on cHL.
Article
Oncology
Claire Lamaison, Juliette Ferrant, Pauline Gravelle, Alexandra Traverse-Glehen, Herve Ghesquieres, Marie Tosolini, Cedric Rossi, Loic Ysebaert, Pierre Brousset, Camille Laurent, Charlotte Syrykh
Summary: This study evaluated the dynamic expression of 586 immune-related genes in a cohort of 42 classical Hodgkin lymphoma (cHL) patients. A 19-gene immune signature predictive of cHL relapse was identified, which was strongly dependent on histological subtype.
Article
Immunology
Imen Zawati, Olfa Adouni, Maroua Manai, Majdi Nagara, Moisis Tacam, Carolina Reduzzi, Amor Gamoudi, Mohamed Manai
Summary: This study explores the significance of different tumor-infiltrated immune cells and subpopulation ratios in the tumor microenvironment of Classical Hodgkin lymphoma (CHL). The FOXP3+/CD68+ ratio potentially predicts the outcomes of CHL and provides valuable information for guiding clinical treatment.
Article
Oncology
Dominique Fonseca Rodrigues Lacet, Cristiano Claudino Oliveira
Summary: This study investigated tumor markers in the microenvironment of classical Hodgkin lymphoma (CHL) and analyzed their interactions with clinical-morphological aspects. The results showed that CD20+ patients had shorter time-to-cure, PD-1 negative patients had shorter time-to-cure and higher death rates, patients with fewer plasma cells in the microenvironment tended to be cured earlier, and higher vascular density was associated with lower frequency of B symptoms and disease recurrence in CHL patients.
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
(2022)
Article
Medicine, Research & Experimental
Angelica Maria Gamboa-Cedeno, Mariangeles Diaz, Nancy Cristaldo, Victoria Otero, Natalia Schutz, Dorotea Fantl, Silvana Cugliari, Marta Zerga, Erica Rojas-Bilbao, Federico Jauk, Hernan Garcia Rivello, Myriam Nunez, Stella Maris Ranuncolo
Summary: The study highlights the potential of BCL-2 as a prognostic biomarker and a new therapeutic target in classical Hodgkin Lymphoma (cHL). Additionally, it reveals the cytotoxic effect of venetoclax in human cHL cell lines for the first time.
Review
Oncology
Alessandro Cellini, Federico Scarmozzino, Francesco Angotzi, Edoardo Ruggeri, Angelo Paolo Dei Tos, Livio Trentin, Marco Pizzi, Andrea Visentin
Summary: Immune evasion through overexpression of PD-L1 and PD-L2 proteins and the role of the microenvironment are key factors in classical Hodgkin Lymphoma. This review discusses the strategies used by cHL to create an immunosuppressive microenvironment and achieve optimal immune evasion, as well as the success and resistance mechanisms of checkpoint inhibitors in cHL immunotherapy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Pathology
Akiko Miyagi Maeshima, Hirokazu Taniguchi, Daiki Hattori, Hirokazu Sasaki, Yoshikazu Hori, Shinichi Makita, Noriko Iwaki, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Koji Izutsu
Summary: Histopathological diagnoses of rare CD3- and CD20-negative extramedullary leukemias/lymphomas are challenging. In this study, 118 cases of CD3- CD20- extramedullary leukemias/lymphomas were reported, with anaplastic large cell lymphoma being the most common (41%), followed by large B-cell lymphoma/plasmablastic lymphoma (30%).
Article
Oncology
Reyizha Nuersulitan, Mingzi Yang, Lan Mi, Meng Wu, Xin Liu, Lingyan Ping, Yan Xie, Weiping Liu, Yuqin Song, Jun Zhu
Summary: The study demonstrates that the survival probability of patients with classical Hodgkin's lymphoma increases over time while the hazard of failure decreases gradually. Early-stage patients have lower failure hazard rates, and advanced-stage patients also experienced significant decreases in failure hazard rates after 3 years.
CANCER MANAGEMENT AND RESEARCH
(2021)
